Exploiting tyrosinase expression and activity in melanocytic tumors: Quercetin and the central role of p53

Integrative Cancer Therapies

Volumn 10, Issue 4, 2011, Pages 328-340

  Vargas, Ashley J ^a   Sittadjody, Sivanandane ^a   Thangasamy, Thilakavathy ^a   Mendoza, Erin E ^a   Limesand, Kirsten H ^a   Burd, Randy ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

melanoma; neuroblastoma; p53; quercetin; tyrosinase

Indexed keywords

DACARBAZINE; MONOPHENOL MONOOXYGENASE; PROTEIN P53; QUERCETIN; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG TARGETING; ENZYME INDUCTION; HUMAN; MELANOMA; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE;

ANIMALS; APOPTOSIS; GENES, P53; HUMANS; MELANOMA; MONOPHENOL MONOOXYGENASE; NEUROBLASTOMA; QUERCETIN; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84855218005     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410391661     Document Type: Article

References (111)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007 ; 445: 851-857
2. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003 ; 2: 753-763
3. Quaglino P, Osella-Abate S, Cappello N, et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res. 2007 ; 17: 75-82 (Pubitemid 46673900)
4. Boyle JL, Haupt HM, Stern JB, Multhaupt HA. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch Pathol Lab Med. 2002 ; 126: 816-822 (Pubitemid 34761639)
5. Jordan AM, Khan TH, Malkin H, Osborn HM. Synthesis and analysis of urea and carbamate prodrugs as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT). Bioorg Med Chem. 2002 ; 10: 2625-2633 (Pubitemid 34626225)
6. Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA. Melanogenesis-targeted anti-melanoma pro-drug development: effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur J Cancer. 1997 ; 33: 135-143 (Pubitemid 27099581)
7. Altaner C. Prodrug cancer gene therapy. Cancer Lett. 2008 ; 270: 191-201
8. Drexler I, Antunes E, Schmitz M, et al. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201- restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 1999 ; 59: 4955-4963 (Pubitemid 29472901)
9. Colella TA, Bullock TN, Russell LB, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000 ; 191: 1221-1232
10. Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res. 2004 ; 10: 5381-5390 (Pubitemid 39100475)
11. Meyer RG, Britten CM, Siepmann U, et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother. 2005 ; 54: 453-467 (Pubitemid 40543685)
12. Morrison ME, Yagi MJ, Cohen G. In vitro studies of 2,4- dihydroxyphenylalanine, a prodrug targeted against malignant melanoma cells. Proc Natl Acad Sci U S A. 1985 ; 82: 2960-2964 (Pubitemid 15097772)
13. Pankovich JM, Jimbow K, Ito S. 4-S-cysteaminylphenol and its analogues as substrates for tyrosinase and monoamine oxidase. Pigment Cell Res. 1990 ; 3: 146-149
14. Prezioso JA, Damodaran KM, Wang N, Bloomer WD. Mechanism(s) regulating inhibition of thymidylate synthase and growth by gamma-L-glutaminyl-4-hydroxy-3- iodobenzene, a novel melanin precursor, in melanogenic melanoma cells. Biochem Pharmacol. 1993 ; 45: 473-481 (Pubitemid 23042648)
15. Jawaid S, Khan TH, Osborn HM, Williams NA. Tyrosinase activated melanoma prodrugs. Anticancer Agents Med Chem. 2009 ; 9: 717-727
16. Surveillance, Epidemiology, and End Results (SEER) Program. Washington, DC: National Cancer Institute ; 2005 :
17. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clin Proc. 2006 ; 81: 500-507
18. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 ; 19: 3635-3648 (Pubitemid 32786276)
19. Little JW. Melanoma: etiology, treatment, and dental implications. Gen Dent. 2006 ; 54: 61-66 (Pubitemid 43266259)
20. Nieto MA. The early steps of neural crest development. Mech Dev. 2001 ; 105: 27-35 (Pubitemid 32586757)
21. Gilchrest BA, Park HY, Eller MS, Yaar M. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol. 1996 ; 63: 1-10
22. Slominski A, Paus R, Mazurkiewicz J. Pro-opiomelanocortin expression and potential function of pro-opiomelanocortin products during induced hair growth in mice. Ann N Y Acad Sci. 1991 ; 642: 459-461
23. Jimbow K, Iwashina T, Alena F, Yamada K, Pankovich J, Umemura T. Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma. J Invest Dermatol. 1993 ; 100: 231S - 238S (Pubitemid 23051704)
24. Halaban R. Pigmentation in melanomas: changes manifesting underlying oncogenic and metabolic activities. Oncol Res. 2002 ; 13: 3-8 (Pubitemid 38166399)
25. Schallreuter KU, Kothari S, Chavan B, Spencer JD. Regulation of melanogenesis-controversies and new concepts. Exp Dermatol. 2008 ; 17: 395-404 (Pubitemid 351513953)
26. Park HY, Perez JM, Laursen R, Hara M, Gilchrest BA. Protein kinase C-beta activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain. J Biol Chem. 1999 ; 274: 16470-16478
27. Ponnazhagan S, Hou L, Kwon BS. Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. J Invest Dermatol. 1994 ; 102: 744-748 (Pubitemid 24144255)
28. Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol. 1994 ; 14: 8058-8070 (Pubitemid 24373554)
29. Cui R, Widlund HR, Feige E, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007 ; 128: 853-864 (Pubitemid 46341415)
30. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003 ; 3: 203-216 (Pubitemid 37328872)
31. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009 ; 23: 125-143
32. Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006 ; 42: 2081-2091
33. Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997 ; 19: 428-432 (Pubitemid 28076487)
34. Bonfigli A, Zarivi O, Colafarina S, et al. Human glioblastoma ADF cells express tyrosinase, L-tyrosine hydroxylase and melanosomes and are sensitive to L-tyrosine and phenylthiourea. J Cell Physiol. 2006 ; 207: 675-682 (Pubitemid 43668230)
35. Becker K, Marchenko ND, Maurice M, Moll UM. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ. 2007 ; 14: 1350-1360 (Pubitemid 46965264)
36. Child ES, Mann DJ. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle. 2006 ; 5: 1313-1319 (Pubitemid 43894287)
37. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004 ; 22: 1118-1125 (Pubitemid 41095046)
38. Flaherty LE. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. Cancer J Sci Am. 2000 ; 6 (suppl 1). S15 - S20
39. Salvati M, D'Elia A, Formichella AI, Frati A. Insights into pharmacotherapy of malignant glioma in adults. Expert Opin Pharmacother. 2009 ; 10: 2279-2290
40. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol. 2002 ; 29: 518-524 (Pubitemid 35178291)
41. Gasowska-Bajger B, Wojtasek H. Indirect oxidation of the antitumor agent procarbazine by tyrosinase-possible application in designing anti-melanoma prodrugs. Bioorg Med Chem Lett. 2008 ; 18: 3296-3300 (Pubitemid 351718327)
42. Thangasamy T, Sittadjody S, Lanza-Jacoby S, Wachsberger P, Limesand K, Burd R. Quercetin selectively inhibits bioreduction and enhances apoptosis in melanoma cells that overexpress tyrosinase. Nutr Cancer. 2007 ; 59: 1-11
43. Thangasamy T, Sittadjody S, Limesand KH, Burd R. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol. 2008 ; 30: 371-387
44. Jordan AM, Khan TH, Osborn HM, Photiou A, Riley PA. Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma. Bioorg Med Chem. 1999 ; 7: 1775-1780 (Pubitemid 29457673)
45. Ulasov IV, Rivera AA, Nettelbeck DM, et al. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. Int J Oncol. 2007 ; 31: 1177-1185
46. Vargas AJ, Burd R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev. 2010 ; 68: 418-428
47. Murota K, Terao J. Antioxidative flavonoid quercetin: implication of its intestinal absorption and metabolism. Arch Biochem Biophys. 2003 ; 417: 12-17 (Pubitemid 36960043)
48. Alia M, Mateos R, Ramos S, Lecumberri E, Bravo L, Goya L. Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). Eur J Nutr. 2006 ; 45: 19-28 (Pubitemid 43221280)
49. Thangasamy T, Sittadjody S, Burd R Complementary and Alternative Therapies and the Aging Population. Watson RR, ed. Amsterdam, Netherlands: Elsevier ; 2009: 563-584.
50. Ferry DR, Smith A, Malkhandi J, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996 ; 2: 659-668 (Pubitemid 26133468)
51. Egert S, Wolffram S, Bosy-Westphal A, et al. Daily quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy humans. J Nutr. 2008 ; 138: 1615-1621
52. Erlund I, Kosonen T, Alfthan G, et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol. 2000 ; 56: 545-553
53. Hollman PC, van Trijp JM, Buysman MN, et al. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 1997 ; 418: 152-156 (Pubitemid 27514436)
54. Moon YJ, Wang L, DiCenzo R, Morris ME. Quercetin pharmacokinetics in humans. Biopharm Drug Dispos. 2008 ; 29: 205-217 (Pubitemid 351802843)
55. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro. 2006 ; 20: 187-210 (Pubitemid 43087702)
56. Hemaiswarya S, Doble M. Potential synergism of natural products in the treatment of cancer. Phytother Res. 2006 ; 20: 239-249
57. Simonova M, Wall A, Weissleder R, Bogdanov A. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res. 2000 ; 60: 6656-6662
58. Pearson VC, Ferguson J, Rogers PM, Kelland LR, Robins DJ. Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S- cysteaminylphenol. Oncol Res. 2003 ; 13: 503-512
59. Thomas PD, Kishi H, Cao H, et al. Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogs. J Invest Dermatol. 1999 ; 113: 928-934 (Pubitemid 30013333)
60. Johnson MK, Loo G. Effects of epigallocatechin gallate and quercetin on oxidative damage to cellular DNA. Mutat Res. 2000 ; 459: 211-218 (Pubitemid 30254308)
61. Awad HM, Boersma MG, Boeren S, et al. Identification of o-quinone/quinone methide metabolites of quercetin in a cellular in vitro system. FEBS Lett. 2002 ; 520: 30-34 (Pubitemid 34607268)
62. Nagata H, Takekoshi S, Takeyama R, Homma T, Yoshiyuki OR. Quercetin enhances melanogenesis by increasing the activity and synthesis of tyrosinase in human melanoma cells and in normal human melanocytes. Pigment Cell Res. 2004 ; 17: 66-73 (Pubitemid 38166441)
63. Takeyama R, Takekoshi S, Nagata H, Osamura RY, Kawana S. Quercetin-induced melanogenesis in a reconstituted three-dimensional human epidermal model. J Mol Histol. 2004 ; 35: 157-165 (Pubitemid 40585326)
64. Metodiewa D, Jaiswal AK, Cenas N, Dickancaite E, Segura-Aguilar J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free Radic Biol Med. 1999 ; 26: 107-116 (Pubitemid 29001498)
65. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997 ; 88: 323-331 (Pubitemid 27131374)
66. Michalak E, Villunger A, Erlacher M, Strasser A. Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun. 2005 ; 331: 786-798 (Pubitemid 40615509)
67. Khlgatian MK, Hadshiew IM, Asawanonda P, et al. Tyrosinase gene expression is regulated by p53. J Invest Dermatol. 2002 ; 118: 126-132 (Pubitemid 34107433)
68. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat Rev Cancer. 2002 ; 2: 605-615 (Pubitemid 37328927)
69. DeYoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene. 2007 ; 26: 5169-5183 (Pubitemid 47237632)
70. Muller M, Schilling T, Sayan AE, et al. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 2005 ; 12: 1564-1577 (Pubitemid 41679162)
71. Di VA, Sessa F, Casciano I, et al. Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. Int J Oncol. 2009 ; 34: 449-456
72. Tannapfel A, Wasner M, Krause K, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999 ; 91: 1154-1158 (Pubitemid 29330554)
73. Tannapfel A, Engeland K, Weinans L, et al. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer. 1999 ; 80: 1069-1074 (Pubitemid 29233931)
74. Douc-Rasy S, Barrois M, Echeynne M, et al. DeltaN-p73alpha accumulates in human neuroblastic tumors. Am J Pathol. 2002 ; 160: 631-639 (Pubitemid 34160341)
75. Thangasamy T, Sittadjody S, Mitchell GC, et al. Quercetin abrogates chemoresistance in melanoma cells by modulating DeltaNp73. BMC Cancer. 2010 ; 10: 282
76. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2001 ; 98: 1188-1193 (Pubitemid 32121208)
77. Metodiewa D, Koceva-Chyla A, Kochman A, Skolimowski J, Jozwiak Z. Antiproliferative and cytotoxic effects of N, N-diethylaminoethyl ethers of flavanone oximes: a comparison with anthracycline(s), anthraquinone and nitroxides action. Anticancer Res. 1999 ; 19: 1255-1260 (Pubitemid 29257568)
78. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med. 2000 ; 29: 323-333
79. Ye R, Goodarzi AA, Kurz EU, et al. The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 ; 3: 235-244 (Pubitemid 38177245)
80. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res. 2004 ; 2: 371-386 (Pubitemid 39031071)
81. Yu J, Zhang L. No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell. 2003 ; 4: 248-249 (Pubitemid 37329788)
82. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001 ; 7: 683-694 (Pubitemid 32706359)
83. Lee DH, Kim C, Zhang L, Lee YJ. Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol. 2008 ; 75: 2020-2033
84. Karst AM, Dai DL, Cheng JQ, Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res. 2006 ; 66: 9221-9226 (Pubitemid 44521143)
85. Jeong JH, An JY, Kwon YT, Rhee JG, Lee YJ. Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression. J Cell Biochem. 2009 ; 106: 73-82
86. Ma L, Feugang JM, Konarski P, et al. Growth inhibitory effects of quercetin on bladder cancer cell. Front Biosci. 2006 ; 11: 2275-2285 (Pubitemid 43822559)
87. Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003 ; 197: 93-98 (Pubitemid 36859996)
88. Tan J, Wang B, Zhu L. Regulation of survivin and Bcl-2 in HepG2 cell apoptosis induced by quercetin. Chem Biodivers. 2009 ; 6: 1101-1110
89. Zhang Q, Zhao XH, Wang ZJ. Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol In Vitro. 2009 ; 23: 797-807
90. Aalinkeel R, Bindukumar B, Reynolds JL, et al. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate. 2008 ; 68: 1773-1789
91. Hassan M, Alaoui A, Feyen O, et al. The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways. Oncogene. 2008 ; 27: 4557-4568
92. Ito H, Kanzawa T, Miyoshi T, et al. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther. 2005 ; 16: 685-698 (Pubitemid 40864269)
93. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res. 2006 ; 66: 9636-9645 (Pubitemid 44623663)
94. Li J, Lee B, Lee AS. Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem. 2006 ; 281: 7260-7270 (Pubitemid 43847494)
95. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem. 2009 ; 279: 8627-8634 (Pubitemid 38295917)
96. Armstrong JL, Veal GJ, Redfern CP, Lovat PE. Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis. 2007 ; 12: 613-622
97. Fricker M, Papadia S, Hardingham GE, Tolkovsky AM. Implication of TAp73 in the p53-independent pathway of Puma induction and Puma-dependent apoptosis in primary cortical neurons. J Neurochem. 2010 ; 114: 772-783
98. Van MT, Speleman F, Vermeulen J, et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006 ; 66: 9646-9655 (Pubitemid 44623664)
99. Maeda K, Feyles V, McGarry RC, Jerry LM. Melanocytic differentiation of human neuroblastoma: expression of a human melanosome-associated antigen. J Invest Dermatol. 1990 ; 95: 665-670
100. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A. 2002 ; 99: 3099-3104 (Pubitemid 34240592)
101. Russo M, Nigro P, Rosiello R, D'Arienzo R, Russo GL. Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines. Leukemia. 2007 ; 21: 1130-1133 (Pubitemid 46672100)
102. Russo M, Palumbo R, Mupo A, et al. Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase C-alpha. Oncogene. 2003 ; 22: 3330-3342 (Pubitemid 36717126)
103. Russo M, Palumbo R, Tedesco I, et al. Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line. FEBS Lett. 1999 ; 462: 322-328
104. Gugler R, Leschik M, Dengler HJ. Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol. 1975 ; 9: 229-234
105. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003 ; 36: 79-87 (Pubitemid 36126394)
106. Manach C, Morand C, Demigne C, Texier O, Regerat F, Remesy C. Bioavailability of rutin and quercetin in rats. FEBS Lett. 1997 ; 409: 12-16 (Pubitemid 27248557)
107. Morand C, Crespy V, Manach C, Besson C, Demigne C, Remesy C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol. 1998 ; 275: R212 - R219
108. Silberberg M, Morand C, Manach C, Scalbert A, Remesy C. Co-administration of quercetin and catechin in rats alters their absorption but not their metabolism. Life Sci. 2005 ; 77: 3156-3167 (Pubitemid 41433317)
109. Choi EJ, Chee KM, Lee BH. Anti- and prooxidant effects of chronic quercetin administration in rats. Eur J Pharmacol. 2003 ; 482: 281-285 (Pubitemid 37505954)
110. Choi EJ, Lee BH, Lee K, Chee KM. Long-term combined administration of quercetin and daidzein inhibits quercetin-induced suppression of glutathione antioxidant defenses. Food Chem Toxicol. 2005 ; 43: 793-798 (Pubitemid 40385120)
111. Utesch D, Feige K, Dasenbrock J, et al. Evaluation of the potential in vivo genotoxicity of quercetin. Mutat Res. 2008 ; 654: 38-44